Effects of panax notoginseng saponins on the osteogenic differentiation of rabbit bone mesenchymal stem cells through TGF-β1 signaling pathway

Wang, Yan; Huang, Xuanping; Tang, Yiyao; Lin, Haiyun; Zhou, Nuo

doi:10.1186/s12906-016-1304-9

Cited by 14 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation is proved that bacoside‐A can able to enhance osteogenic differentiation of hBMSCs. This result is concordant with previous studies, which investigated the osteogenic differentiation effects of other saponins compounds on MSCs 35,36,38‐43 …”

Section: Discussionsupporting

confidence: 93%

“…It can able to prevent deterioration of bone tissues by enhancing bone formation through osteoblastogenesis and suppressing bone resorption through osteoclastogenesis. Numerous studies have shown about varieties of saponin compounds including tenuigenin, 38 platycodon, 35 panax notoginseng, 36,39 ginsenoside, 40 diosgenin, 41 asperosaponin VI 42 , terpenoid and steroidal saponins, 43 which stimulates osteoblast differentiation and inhibits osteoclastogenesis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Osteogenic differentiation potential of human bone marrow‐derived mesenchymal stem cells enhanced by bacoside‐A

Ramesh

2020

Cell Biochemistry & Function

View full text Add to dashboard Cite

Stem cell therapy is growing rapidly to treat numerous diseases including bone‐associated diseases. Mesenchymal stem cells (MSCs) are most commonly preferred to treat bone diseases because it possesses high osteogenic potency. Though, to obtain maximum osteogenic efficiency of MSCs is challenging. Therefore, this study was planned to evaluate the osteogenic efficiency of human bone marrow derived mesenchymal stem cells (hBMSCs) by bacoside‐A. This study was investigated the activity of alkaline phosphatase (ALP) and expressions of the genes specific to osteogenic regulation mainly runt‐related transcription factor 2 (Runx2), osterix (Osx), osteocalcin (OCN) and collagen type Iα1 (Col I α1) in hBMSCs cultured under osteogenic conditions at different concentrations of bacoside‐A for 14 days. The results of this study depicted significant upregulation in the activity of ALP and expressions of osteogenic regulator genes in bacoside‐A treated cells when compared with control cells. Besides, expressions of glycogen synthase kinase‐3β (GSK‐3β) and Wnt/β‐catenin were evaluated; these expressions were also significantly increased in bacoside‐A treated cells when compared with control cells. This result provides a further supporting evidence of bacoside‐A role on osteogenesis in hBMSCs. The present study suggest that bacoside‐A will be applied to ameliorate the process of osteogenesis in hBMSCs to repair damaged bone structure during MSC‐based therapy; this will be an excellent and auspicious treatment for bone‐associated disorders including osteoporosis. Significance of the study Osteoporosis is a bone metabolic disorder characterized by an imbalance between the activity of osteoblastic bone formation and osteoclastic bone resorption that disrupts the bone microarchitecture. Current anti‐osteoporotic drugs are inhibiting bone resorption, but they are unable to restore the bone structure due to extreme bone remodelling process and causes numerous side effects. The finding of natural bioactive compounds with osteogenic property is very essential for osteoporosis treatment. This study was reported that bacoside‐A ameliorated osteogenic differentiation of hBMSCs through upregulation of osteogenic differentiation genes and Wnt/β‐catenin signalling pathway. This result is indicating that bacoside‐A may be useful for osteoporosis treatments.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Osteogenic differentiation potential of human bone marrow‐derived mesenchymal stem cells enhanced by bacoside‐A

Ramesh

2020

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Panax notoginseng has beneficial effects on atherosclerotic diseases such as cardiovascular disease (Yang et al , ), cerebral ischemic disease (Shi et al , ) and other diseases including diabetes (Uzayisenga et al , ; Kitamura et al , ), tumor (Yang et al , ; Li et al , ; Lee et al , ), hepatic injury (Wang et al , ; Zhang et al , ) and bone fracture (Wang et al, ). For in the cardiovascular system, it attenuates atherosclerosis, through inhibiting the formation of foam cells and lowering cholesterol ester level (Jia et al , ), demonstrating antiinflammatory and anti‐adhesion effects (Yuan et al , ) and reducing the size of atherosclerotic plaques (Liu et al , ).…”

Section: Discussionmentioning

confidence: 99%

Panax notoginsengPreparations for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

This paper assessed the evidence of Panax notoginseng preparations in patients suffering from UAP using meta-analysis and systematic review methods. Methods were according to the Cochrane Handbook and analysed using Revman 5.3. A search of PubMed, Cochrane Library, Embase, MEDLINE, Chinese national knowledge infrastructure (CNKI), Vip information database, Wanfang data and Chinese Biomedical Literature Database (SinoMed) was conducted to identify randomized controlled trials (RCTs) of P. notoginseng preparations on UAP regardless of blinding, sex and language. The outcomes include all-cause mortality, cardiac mortality, cardiovascular events, UAP symptoms, improvement of electrocardiogram and adverse events. Eighteen RCTs including 1828 patients were identified. The level of reporting is generally poor. Among 18 studies, 16 studies were prescribed P. notoginseng injections, and two studies were oral P. notoginseng preparations. Reduction of cardiovascular events (RR:0.35;95% CI:0.13 to 0.94), alleviation of angina pectoris symptoms (RR:1.23;95% CI 1.18 to 1.29), improvement of ECG (RR:1.22;95% CI 1.15 to 1.28) and reduced frequency of angina pectoris (MD:-1.48; 95% CI -2.49 to -0.48) were observed. Cardiac mortality and duration of angina pectoris were not statistically significant. Panax notoginseng is beneficial to UAP patients; the results of these reviews may have important implications to clinical work. Copyright © 2017 John Wiley & Sons, Ltd.

show abstract

“…Some previous studies confirmed that Panax notoginseng saponins facilitate the osteogenic process of the skeletal progenitor cells in vitro [ 14 , 15 ], including the proliferation, differentiation, and mineralization. The possible mechanism is that PNS promotes the expression of downstream osteogenesis-related genes by activating ERK and p38 [ 16 ] as well as TGF- β 1 [ 17 ] signaling pathways. Angiogenesis plays an indispensable role in osteogenesis [ 18 ], and the most important pharmacological function of PNS is its vasoactive effect, indicating that PNS could preserve bone mass by promoting the coupling of angiogenesis and osteogenesis during osteoporosis.…”

Section: Introductionmentioning

confidence: 99%

Panax Notoginseng Saponins Prevent Bone Loss by Promoting Angiogenesis in an Osteoporotic Mouse Model

Chen

Zou

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

With the aging of the population and the extension of life expectancy, osteoporosis is becoming a global epidemic. Although there are several drugs used to treat osteoporosis in clinical practice, such as parathyroid hormone or bisphosphonates, they all have some serious side effects. Therefore, a safer drug is called for osteoporosis, especially for the prevention in the early stage of the disease, not only the treatment in the later stage. Panax notoginseng saponin (PNS), a traditional Chinese herb, has been used as anti-ischemic drug due to its function on improving vascular circulation. In order to verify whether Panax notoginseng saponins (PNS) could be used to prevent osteoporosis, ovariectomy (OVX) was induced in female C57BL/C6J mice, followed by orally administration with 40 mg/kg/d, 80 mg/kg/d, and 160 mg/kg/d of three different dosages of PNS for 9 weeks. Serum biochemical analysis, micro-CT, histological evaluation, and immunostaining of markers of osteogenesis and angiogenesis were performed in the sham, osteoporotic (OVX), and treatment (OVX+PNS) groups. Micro-CT and histological evaluation showed that compared to sham group, the bone mass of OVX group reduced significantly, while it was significantly restored in the moderate-dose PNS (40 mg/kg and 80 mg/kg) treatment groups. The expression of CD31 and osteocalcin (OCN) in the bone tissue of treatment group also increased, suggesting that PNS activated osteogenesis and angiogenesis, which subsequently increased the bone mass. These results confirmed the potential function of PNS on the prevention of osteoporosis. However, in the high dose of PNS (160 mg/kg) group, the antiosteoportic effect had been eliminated, which also suggested the importance of proper dose of PNS for the prevention and treatment of osteoporosis in postmenopausal women.

show abstract

Effects of panax notoginseng saponins on the osteogenic differentiation of rabbit bone mesenchymal stem cells through TGF-β1 signaling pathway

Cited by 14 publications

References 23 publications

Osteogenic differentiation potential of human bone marrow‐derived mesenchymal stem cells enhanced by bacoside‐A

Osteogenic differentiation potential of human bone marrow‐derived mesenchymal stem cells enhanced by bacoside‐A

Panax notoginsengPreparations for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis

Panax Notoginseng Saponins Prevent Bone Loss by Promoting Angiogenesis in an Osteoporotic Mouse Model

Contact Info

Product

Resources

About